Concepedia

Andrew K. Dilger

AK

Statistics

Publications

10

Citations

586

H-Index

10

Active since

2007

Affiliations

Bristol-Myers Squibb (United States)(Current)

Princeton University

Bristol-Myers Squibb (Sweden)

Andrew K. Dilger is an author at Bristol-Myers Squibb (United States) specializing in organic chemistry, engineering, and chemistry.

Top concepts

Publications per year

2007–2021

10

Publications

10

Selective C−H Halogenation with a Highly Fluorinated Manganese Porphyrin

Gang Li, Andrew K. Dilger, Peter T. W. Cheng et al. · Angewandte Chemie International Edition · 2017 · 99 citations

Discovery of Milvexian, a High-Affinity, Orally Bioavailable Inhibitor of Factor XIa in Clinical Studies for Antithrombotic Therapy

Andrew K. Dilger, Kumar B. Pabbisetty, James R. Corte et al. · Journal of Medicinal Chemistry · 2021 · 93 citations · Full text

Oxy-Allyl Cation Catalysis: An Enantioselective Electrophilic Activation Mode

Chun Liu, E. Zachary Oblak, Mark N. Vander Wal et al. · Journal of the American Chemical Society · 2016 · 88 citations · Full text

, , +13

Development of a generic activation mode: nucleophilic α-substitution of ketones via oxy-allyl cations

Mark N. Vander Wal, Andrew K. Dilger, David W. C. MacMillan · Chemical Science · 2013 · 84 citations

, , +13

Milvexian, an orally bioavailable, small‐molecule, reversible, direct inhibitor of factor XIa: In vitro studies and in vivo evaluation in experimental thrombosis in rabbits

Pancras C. Wong, Earl J. Crain, Jeffrey M. Bozarth et al. · Journal of Thrombosis and Haemostasis · 2021 · 58 citations · Full text

, , +9

1–5 of 10